Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study

Abstract

Extension of randomized, double-blind clinical study evaluating laquinimod verus placebo showed long-term efficacy of this anti-inflammatory immunomodulatory drug in relapsing-remitting multiple sclerosis and its long-term safety

Keywords

• Multiple sclerosis
• relapsing-remitting
• immunomodulator
• MRI
• Gadolinium-enhanced T1 lesions
• controlled-trial
• mri
• standard